Company Filing History:
Years Active: 2017
Title: Charlie Fehl - Innovator in Cancer Treatment
Charlie Fehl is an accomplished inventor based in Farmington, MI (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds.
Latest Patents
Charlie Fehl holds a patent for "Inhibitors of CYP17A1." This patent includes compounds according to formula I or II, which are beneficial in treating various cancers, such as leukemia, colon cancer, breast cancer, and prostate cancer. The compounds work by inhibiting CYP17A1, providing a promising avenue for cancer therapy. He has 1 patent to his name.
Career Highlights
Charlie Fehl is affiliated with the University of Kansas Medical Center Research Institute, where he conducts his research. His work focuses on developing pharmaceutical compositions and methods that incorporate his patented compounds, aiming to improve treatment outcomes for cancer patients.
Collaborations
Charlie has collaborated with notable colleagues, including Jeffrey Aube and Emily E. Scott, who contribute to his research efforts and enhance the impact of his work in the medical field.
Conclusion
In summary, Charlie Fehl is a dedicated inventor whose work in cancer treatment through innovative compounds showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his research continues to inspire future innovations.